Telix Pharmaceuticals Limited Stock Market Value
| TLX Stock | 6.54 0.11 1.71% |
| Symbol | Telix |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Telix Pharmaceuticals. If investors know Telix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Telix Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share 0.02 | Revenue Per Share | Quarterly Revenue Growth 0.589 | Return On Assets | Return On Equity |
The market value of Telix Pharmaceuticals is measured differently than its book value, which is the value of Telix that is recorded on the company's balance sheet. Investors also form their own opinion of Telix Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Telix Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Telix Pharmaceuticals' market value can be influenced by many factors that don't directly affect Telix Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Telix Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Telix Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Telix Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Telix Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Telix Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Telix Pharmaceuticals.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Telix Pharmaceuticals on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Telix Pharmaceuticals Limited or generate 0.0% return on investment in Telix Pharmaceuticals over 90 days. Telix Pharmaceuticals is related to or competes with Mirum Pharmaceuticals, Soleno Therapeutics, Dyne Therapeutics, ADMA Biologics, Belite Bio, Ligand Pharmaceuticals, and ACADIA Pharmaceuticals. Telix Pharmaceuticals is entity of United States More
Telix Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Telix Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Telix Pharmaceuticals Limited upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.23) | |||
| Maximum Drawdown | 16.5 | |||
| Value At Risk | (5.54) | |||
| Potential Upside | 4.24 |
Telix Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Telix Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Telix Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Telix Pharmaceuticals historical prices to predict the future Telix Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.16) | |||
| Jensen Alpha | (0.68) | |||
| Total Risk Alpha | (0.84) | |||
| Treynor Ratio | (0.57) |
Telix Pharmaceuticals February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.16) | |||
| Market Risk Adjusted Performance | (0.56) | |||
| Mean Deviation | 2.34 | |||
| Coefficient Of Variation | (493.40) | |||
| Standard Deviation | 3.0 | |||
| Variance | 9.02 | |||
| Information Ratio | (0.23) | |||
| Jensen Alpha | (0.68) | |||
| Total Risk Alpha | (0.84) | |||
| Treynor Ratio | (0.57) | |||
| Maximum Drawdown | 16.5 | |||
| Value At Risk | (5.54) | |||
| Potential Upside | 4.24 | |||
| Skewness | 0.3049 | |||
| Kurtosis | 0.7638 |
Telix Pharmaceuticals Backtested Returns
Telix Pharmaceuticals owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.17, which indicates the firm had a -0.17 % return per unit of risk over the last 3 months. Telix Pharmaceuticals Limited exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Telix Pharmaceuticals' Coefficient Of Variation of (493.40), risk adjusted performance of (0.16), and Variance of 9.02 to confirm the risk estimate we provide. The entity has a beta of 1.08, which indicates a somewhat significant risk relative to the market. Telix Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Telix Pharmaceuticals is expected to follow. At this point, Telix Pharmaceuticals has a negative expected return of -0.5%. Please make sure to validate Telix Pharmaceuticals' jensen alpha, kurtosis, as well as the relationship between the Kurtosis and price action indicator , to decide if Telix Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.70 |
Good predictability
Telix Pharmaceuticals Limited has good predictability. Overlapping area represents the amount of predictability between Telix Pharmaceuticals time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Telix Pharmaceuticals price movement. The serial correlation of 0.7 indicates that around 70.0% of current Telix Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.7 | |
| Spearman Rank Test | 0.66 | |
| Residual Average | 0.0 | |
| Price Variance | 0.15 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.